Rx-360 Symposium Presentations
On 29 October, Rx-360 conducted a successful Symposium in Germany to discuss many important topics impacting the global pharmaceutical supply chain. Industry Leaders and Regulators presented and provided insights into challenges, expectations and solutions to serve patients with high quality medicines using a robust and reliable supply chain.
The Program discussed:
• Rx-360 Progress Report: Where We Came from and Where We Are Going
• Reasons for Rx-360’s Success and 2015 Goals
• Regulatory Panel: Regulators’ Views on Supply Chain Security Issues
• Protecting Patients from Falsified Medicines Online
• Rx-360 Initiatives
• Supplier-Led Working Group Supplier Assessment Questionnaire (SAQ)
• Rx-360 in Asia (China and India)
• Rx-360 Audit Program
• Supply Chain Security Issues
• Cargo Theft/Dealing with Armed Robbery
• Upstream Supply Chain
• Good Distribution Practices in Africa
• Benefits of Rx-360 Membership for Generic Manufacturers.
To view or download the presentations from the symposium, click here
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.